— Know what they know.
Not Investment Advice

News & Sentiment

Sentiment -53.8 2962 articles 1537 bullish 718 bearish Full Index →
CrowdStrike stock rises after bullish analyst calls

CrowdStrike stock rises after bullish analyst calls

CrowdStrike CRWD shares gained about 1.1% in trading on Tuesday after receiving fresh support from Wall Street, with Loop Capital initiating coverage on the cybersecurity company with a Buy rating and Cantor Fitzgerald reiterating its bullish stance. Loop Capital analyst Yun Kim assigned a $230...
bullish BLSH Invezz 9h ago
📰

Chemed (CHE) Tops Q2 Earnings and Revenue Estimates

Chemed (CHE) delivered earnings and revenue surprises of +9.19% and +1.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues...
📰

Why DaVita HealthCare (DVA) Outpaced the Stock Market Today

In the latest trading session, DaVita HealthCare (DVA) closed at $239.46, marking a +1.33% move from the previous day.
📰

Gilead Sciences (GILD) Laps the Stock Market: Here's Why

Gilead Sciences (GILD) reached $134.32 at the closing of the latest trading day, reflecting a +2.91% change compared to its last close.
📰

Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing

In the most recent trading session, Pfizer (PFE) closed at $25.25, indicating a +2.35% shift from the previous trading day.
📰

Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note

In the most recent trading session, Hims & Hers Health, Inc. (HIMS) closed at $29.32, indicating a -3.04% shift from the previous trading day.
📰

Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Know

In the most recent trading session, Novavax (NVAX) closed at $7.37, indicating a -1.6% shift from the previous trading day.
📰

Eli Lilly (LLY) Rises Higher Than Market: Key Facts

Eli Lilly (LLY) closed the most recent trading day at $1, moving +2.09% from the previous trading session.
These 3 Companies Reported Record Results and Raised Guidanc

These 3 Companies Reported Record Results and Raised Guidance

Abbott Laboratories, Taiwan Semiconductor, and Johnson & Johnson have all delivered strong earnings releases in the Q2 cycle, with each breaking...
📰

United Therapeutics CEO Sells $5 Million of Shares. What Does This Mean for Investors?

Martine Rothblatt exercised options at $135.42 and sold at $530.42 under a pre-established Rule 10b5-1 plan, reducing her stake by just 1% while...
📰

[10-Q] ABBOTT LABORATORIES Quarterly Earnings Report - Stock Titan

[10-Q] ABBOTT LABORATORIES Quarterly Earnings Report  Stock Titan
Analyst Report: Roche Holding AG

Analyst Report: Roche Holding AG

Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings

Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?

AbbVie heads into Q2 earnings with Skyrizi and Rinvoq driving growth as investors weigh Humira declines and the company's long-term outlook.
Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings

Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?

AbbVie heads into Q2 earnings with Skyrizi and Rinvoq driving growth as investors weigh Humira declines and the company's long-term outlook.
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View R

INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised

Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.
📰

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits - Fox Business

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits  Fox BusinessJohnson & Johnson agrees to pay $5.5 billion in talc powder...
📰

Eli Lilly Just Made a $2.8 Billion Bet That Goes Beyond GLP-1 Drugs

The company isn't resting on its laurels.
Centene Q2 Earnings Beat Estimates on Increasing Premiums

Centene Q2 Earnings Beat Estimates on Increasing Premiums

CNC's Q2 earnings and revenues top estimates as stronger premium and service revenues drive results despite lower membership and higher medical costs.
📰

3 Dividend Stocks That Are Crushing the Market in 2026

These stocks are all up more than 28% this year.
📰

AMN or RTO: Which Is the Better Value Stock Right Now?

AMN vs. RTO: Which Stock Is the Better Value Option?
📰

5 Undervalued Price-to-Book Stocks Worth Adding to Your Portfolio

Harmony Biosciences, Invesco, GM, HPE and Quanex made the screen of low price-to-book stocks that also met multiple value metrics.
Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, St

Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down

ALKS posts break-even Q2 earnings and tops revenue estimates as product sales surge, with Lumryz adding momentum. The company maintains its 2026...
Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, St

Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down

ALKS posts break-even Q2 earnings and tops revenue estimates as product sales surge, with Lumryz adding momentum. The company maintains its 2026...
Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, St

Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down

ALKS posts break-even Q2 earnings and tops revenue estimates as product sales surge, with Lumryz adding momentum. The company maintains its 2026...
Here's How LLY's Non-GLP-1 Portfolio Is Poised Ahead of Q2 E

Here's How LLY's Non-GLP-1 Portfolio Is Poised Ahead of Q2 Earnings

Eli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1...
Here's How LLY's Non-GLP-1 Portfolio Is Poised Ahead of Q2 E

Here's How LLY's Non-GLP-1 Portfolio Is Poised Ahead of Q2 Earnings

Eli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1...
📰
📰

Viking Therapeutics Q2 2026 Earnings Preview

Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?

Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?

Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.
ISRG Q2 Earnings Call Signals Durable Demand & U.S. Caution

ISRG Q2 Earnings Call Signals Durable Demand & U.S. Caution

ISRG pairs durable platform demand and higher margin guidance with caution on softer U.S. procedure growth and deferred care.
📰

Compared to Estimates, Incyte (INCY) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended June 2026, it could be worth...
📰

Compared to Estimates, Alkermes (ALKS) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended June 2026, it might be worth...
📰

Centene (CNC) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Centene (CNC) give a sense of how its business performed in the quarter ended June 2026, it might be worth...
📰

Company News for July 28, 2026

Companies in The News Are: ENSG,HOPE,LKFN,HBT
📰

Seeking Clues to Teladoc (TDOC) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Teladoc (TDOC), delve into some of its key metrics to gain a deeper insight...
« Prev 1 2 3 8 Next »

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms